STOCK TITAN

Athira Pharma to Present at Stifel 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Athira Pharma, Inc. (NASDAQ: ATHA), a biopharmaceutical company focused on neurodegenerative diseases, will participate in the Stifel 2022 Healthcare Conference on November 15-16, 2022, in New York City. Management will host a fireside chat on November 16 at 4:45 p.m. EST. Interested parties can access a live webcast through the Investors section of Athira's website, with an archived replay available for 30 days post-event. Athira aims to develop small molecules for conditions like Alzheimer's and Parkinson's disease, targeting the HGF/MET neurotrophic system.

Positive
  • None.
Negative
  • None.

BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira’s management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City. Members of management will participate in a fireside chat on Wednesday, Nov. 16, 2022 at 4:45 p.m. EST.

A live webcast of the fireside chat can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcast will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease dementia, Dementia with Lewy bodies and neuropsychiatric indications. For more information, visit www.athira.com. You can also follow Athira on FacebookLinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:

Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219


FAQ

When will Athira Pharma participate in the Stifel 2022 Healthcare Conference?

Athira Pharma will participate in the Stifel 2022 Healthcare Conference on November 15-16, 2022.

What time is Athira's fireside chat at the Stifel Conference?

The fireside chat is scheduled for November 16, 2022, at 4:45 p.m. EST.

How can I access the webcast of Athira's fireside chat?

The webcast can be accessed through the Investors section of Athira Pharma's website.

What is the focus of Athira Pharma's research?

Athira Pharma focuses on developing small molecules to restore neuronal health and slow neurodegeneration.

Which diseases is Athira targeting in its drug development?

Athira is targeting Alzheimer's disease, Parkinson's disease dementia, and other neuropsychiatric indications.

Athira Pharma, Inc.

NASDAQ:ATHA

ATHA Rankings

ATHA Latest News

ATHA Stock Data

20.71M
31.97M
1.95%
62.14%
4.05%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BOTHELL